Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy

BACKGROUND: The tumor-selective human adenovirus Delta24-RGD is currently under investigation in phase II clinical trials for patients with recurrent glioblastoma (GBM). To improve treatments for patients with GBM, we explored the potential of combining Delta24-RGD with antibodies targeting immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Belcaid, Zineb, Berrevoets, Cor, Choi, John, van Beelen, Edward, Stavrakaki, Eftychia, Pierson, Tessa, Kloezeman, Jenneke, Routkevitch, Denis, van der Kaaij, Mariëlle, van der Ploeg, Alicia, Mathios, Dimitrios, Sleijfer, Stefan, Dirven, Clemens, Lim, Michael, Debets, Reno, Lamfers, Martine L M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212906/
https://www.ncbi.nlm.nih.gov/pubmed/32642679
http://dx.doi.org/10.1093/noajnl/vdaa011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212906/
https://www.ncbi.nlm.nih.gov/pubmed/32642679
http://dx.doi.org/10.1093/noajnl/vdaa011

Ejemplares similares